CoronaryAtlas logo
CoronaryAtlas
Apolipoprotein C-II
Pathway / Lipid retention & oxidation

Apolipoprotein C-II

APOC2lipoprotein

Apolipoprotein C-II modulates triglyceride-rich lipoprotein metabolism and is elevated in acute coronary syndrome.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencehigh
RationaleIncreased in ACS; cofactor for lipoprotein lipase and marker of abnormal lipid metabolism.
Also acts inVascular inflammation
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableNo
Antibody tractableYes
EnsemblENSG00000234906

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
26
C — confounder / Type-II
35
A — assay feasibility
82
E — evidence strength
17
T1DI (composite)
6
Specificity differential (R−C)-8.8
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST)
Method / principle
Immunoturbidimetric/nephelometric; or NMR/ultracentrifugation for subfractions
Reagent / substrate
Anti-apolipoprotein antibody-latex; or NMR profile
Platform
Automated analyzer / NMR
Turnaround · availability
Routine–send-out · Variable

Literature evidence(3)